Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Up 375.0% in June

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) was the target of a large increase in short interest in June. As of June 30th, there was short interest totalling 19,000 shares, an increase of 375.0% from the June 15th total of 4,000 shares. Based on an average daily trading volume, of 21,300 shares, the days-to-cover ratio is currently 0.9 days. Currently, 27.1% of the shares of the stock are short sold.

Salarius Pharmaceuticals Price Performance

Shares of SLRX opened at $2.22 on Friday. Salarius Pharmaceuticals has a 1 year low of $1.81 and a 1 year high of $9.92. The company has a 50 day simple moving average of $3.28 and a two-hundred day simple moving average of $4.12. The firm has a market cap of $1.33 million, a P/E ratio of -0.10 and a beta of 0.92.

Salarius Pharmaceuticals (NASDAQ:SLRX) last announced its quarterly earnings data on Monday, May 13th. The company reported ($3.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($53.60) by $50.32. On average, sell-side analysts anticipate that Salarius Pharmaceuticals will post -214.4 earnings per share for the current year.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.